FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2
  • Home
  • About
  • Projects
    • P1 Lymph-Transplant
    • P2 Modulators of LA
    • N1 Ocular GvHD
    • N2 ABCB5 & Pterygium
    • P4 Ocular Melanoma
    • P5 Myeloid Cells
    • P6 Microglia in AMD
    • P8 Uveitis
    • C1 Eye Imaging
    • C2 Management
    • Publication highlights
  • Team
    • Executive Board
    • Research Groups
    • Central Projects
    • Associated projects
    • Alumni
  • Links
  • Events
    • Guest lectures
    • Retreats
    • Symposium
  • News
✕

Antonia Howaldt accepted into the Cologne Clinician Scientist Program

howald

We proudly announce that Antonia Howaldt has been accepted into the Clinician Scientist Program of the Medical Faculty of the University of Cologne.

Designed for physician-scientists seeking careers that combine research with clinical training, the Cologne Clinician Scientist Program offers a three-year program with protected research time supporting translational research (50% clinical training, 50% research), a mentoring system, and an accompanying individual curriculum.

Antonia Howaldt is a first-year Ophthalmology resident at the Ophthalmology Department of the University of Cologne. She finished her medical studies at Charité University in Berlin in December 2019. In the final year of medical school, she completed clerkships at the Brigham and Women’s Hospital, Harvard Medical School, in Boston, Massachusetts, and the Northwestern Memorial Hospital, Feinberg School of Medicine, in Chicago, Illinois.

Antonia Howaldt has conducted research in the field of human genetics at the Institute of Medical Genetics and Human Genetics of the Charité Berlin and the Max Planck Institute for Molecular Genetics in Berlin. She was previously funded by the Berlin Institute of Health within the Medical Student Research Stipend program for 12 months. Her work led to three peer-reviewed papers and several presentations at scientific meetings.

Projected research at the Department of Ophthalmology will focus on corneal disease. As a member of the FOR 2240 research group, she is part of Project 1 led by Prof. Cursiefen and PD Dr. Felix Bock. As a member of the AG Fuchs’ Endothelial Corneal Dystrophy (FECD), she will investigate the genetics and molecular pathophysiology of FECD and work on clinical corneal imaging under the supervision of Prof. Bachmann and PD Dr. Matthaei.

Related posts

Claus Cursiefen

Claus Cursiefen

January 7, 2023

Rare eye diseases: Eight million euros for research: Funding for four years


Read more
December 15, 2022

Experimental Glaucoma Research Group awarded and funded


Read more
Coronavirus

Coronavirus

May 13, 2020

Retreat 2020 in times of Corona


Read more

News

  • Rare eye diseases: Eight million euros for research: Funding for four years
  • Dr. Sarah Barbara Zwingelberg, is awarded Belmonte Fellowship for research on the neurobiology of the ocular surface
  • Experimental Glaucoma Research Group awarded and funded
  • Leonhard Klein-Preis for Prof. Matthaei
  • 4th Shanghai-Cologne Scientific Symposium

More information

  • Publication highlights
  • Jobs
  • Contact
  • Impressum
  • Datenschutz

Newest publications

Supplemental Anti Vegf A-Therapy Prevents Rebound…(2020)


Bevacizumab Induces Upregulation of Keratin 3 and VEGFA in Human…(2020)


Immune reactions after modern lamellar (DALK, DSAEK, DMEK) versus conventional…(2020)


Contact

Esther Engel
Management Office
DFG Research Unit FOR2240
Department of Ophthalmology
University of Cologne
Kerpener Str. 62
50937 Cologne, Germany

www.for2240.de

Tel. +49 (0)221 478 32845
Fax. +49 (0)221 478 5094
esther.engel@uk-koeln.de

Partnerlogos

© 2021 FOR2240 | Online Marketing von Resulted Lübeck